Compare TALK & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | ETON |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 689.8M |
| IPO Year | N/A | 2018 |
| Metric | TALK | ETON |
|---|---|---|
| Price | $5.20 | $30.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $6.42 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.5M | 358.3K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | $26.02 | $40.90 |
| Revenue Next Year | $21.24 | $47.23 |
| P/E Ratio | $155.55 | ★ N/A |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $2.22 | $13.09 |
| 52 Week High | $5.20 | $32.31 |
| Indicator | TALK | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 63.61 | 72.77 |
| Support Level | $4.59 | $15.63 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.01 | 1.42 |
| MACD | -0.01 | 0.52 |
| Stochastic Oscillator | 83.33 | 79.82 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.